Scott Hensley

Scott Hensley appears in the following:

Two new research papers cast doubt on the new COVID booster

Tuesday, October 25, 2022

Biden received a new COVID booster as part of the administration's push to increase uptake, but two new research papers cast doubt on whether they are any better than the original vaccines.


FDA authorizes first revamp of COVID vaccines to target omicron

Wednesday, August 31, 2022

The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.


Advisers to the FDA back COVID vaccines for the youngest children

Wednesday, June 15, 2022

A committee of experts voted unanimously to recommend that the Food and Drug Administration authorize COVID-19 vaccines from Moderna and Pfizer-BioNTech for children as young as 6-months-old.


Advisers to the FDA back Novavax COVID vaccine

Tuesday, June 07, 2022

Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.


Advisers to FDA weigh in on updated COVID boosters for the fall

Wednesday, April 06, 2022

The vaccines now in use are based on the form of the virus that circulated at the beginning of the pandemic and are less effective against the omicron variant. New options are in the works.


Pfizer-BioNTech will seek authorization for second COVID booster for older adults

Tuesday, March 15, 2022

Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.


The FDA postpones a highly anticipated meeting on the Pfizer vaccine for young kids

Friday, February 11, 2022

"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.


The FDA authorizes a Pfizer booster shot for children ages 12 to 15

Monday, January 03, 2022

The authorization comes in the midst of an explosion of COVID-19 cases nationwide driven by the omicron variant — a surge that has brought a spike in pediatric hospitalizations.


The FDA has authorized Merck's COVID pill for home use — the second in two days

Thursday, December 23, 2021

The medicine, called molnupiravir, is taken twice a day for five days and works by preventing the virus from replicating. Merck says it will have 10 million packs available by the end of the month.


FDA authorizes 1st antiviral pill for COVID

Wednesday, December 22, 2021

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.


CDC narrows use of J&J vaccine due to concerns about rare blood clots

Thursday, December 16, 2021

The agency implemented experts' advice because of a rare and sometimes fatal blood-clotting problem known as TTS. More than 16 million people in the U.S. have received a shot of the J&J vaccine.


Pfizer data shows that its COVID-19 pill is effective against severe disease

Tuesday, December 14, 2021

The research finds that the medicine, called Paxlovid, was effective in preventing hospitalization and death when taken by people with mild to moderate illness within a few days of symptoms.


An FDA panel supports Merck COVID drug in mixed vote

Tuesday, November 30, 2021

If the Food and Drug Administration authorizes use of the drug, called molnupiravir, it would be the first oral COVID-19 treatment that could be taken at home.


CDC backs expansion of COVID boosters for all adults

Friday, November 19, 2021

CDC Director Rochelle Walensky gave the green light to boosters just hours after a panel of vaccine advisors voted unanimously to recommend boosters for anyone 18 and older.


WATCH: Harvard-NPR panel on the fight to tame COVID

Friday, November 12, 2021

Watch an expert panel discuss the latest developments and challenges in the COVID-19 pandemic livestreamed at noon ET on Friday.


Moderna says new data supports its COVID vaccine for kids 6 to 11

Monday, October 25, 2021

Moderna says a study in kids 6 to 11 found two doses of the company's COVID-19 vaccine given 28 days apart produced a strong antibody response.


Pfizer-BioNTech COVID vaccine appears more than 90% effective in kids 5 to 11

Friday, October 22, 2021

The companies studied a 10 microgram vaccine dose in children 5 to 11, a third of the dose used for adults, to minimize side effects and because it still prompts a strong immune response.


CDC backs the rollout of COVID vaccine boosters from Moderna and J&J

Thursday, October 21, 2021

CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.


The FDA authorizes Moderna and J&J COVID vaccine boosters

Wednesday, October 20, 2021

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.


An FDA panel of experts backs J&J COVID vaccine booster

Friday, October 15, 2021

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.